For decades, oral health care has mainly focused on preventing cavities and gum disease. However, scientific research has ...

At AAPA 2025, researchers present the results of a PA-led quality improvement initiative for patients with head and neck cancer.

Key Takeaways Keytruda is approved for resectable locally advanced head and neck squamous cell carcinoma with PD-L1 expression, marking a significant advancement in treatment options. The KEYNOTE-689 ...

Source Reference: Bryan ME, et al "Direct comparison of alternative blood-based approaches for early detection and diagnosis of HPV-associated head and neck cancers" Clin Cancer Res 2025; DOI: 10. ...

Company News Published 06/18/2025, 09:09 AM 0 CEL-SCI applauds FDA approval of Merck’s Keytruda for head and neck cancer CVM -1.19% ...

HMC hosts first patient event to support head and neck cancer survivors Published: 15 Jun 2025 - 08:49 am | Last Updated: 15 Jun 2025 - 08:59 am ...

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous ...

The Rahway, N.J., drug maker said Friday that its treatment, Keytruda, has been approved for adult patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express ...

Smoking, alcohol consumption and betel nut chewing are some of the lifestyle factors that have been linked to head and neck cancer. In the Philippines, more than 7,000 Filipinos are diagnosed with ...

The FDA has started a priority review of MSD's Keytruda as neoadjuvant and adjuvant treatment of locally advanced head and neck squamous cell carcinoma (HNSCC), with a decision due by 23rd June ...

This trial was looking at a treatment called Reolysin in combination with paclitaxel and carboplatin chemotherapy for advanced cancers, including head and neck cancers. Doctors often treat advanced ...

JAVELIN Head and Neck 100 is the first late-stage trial to report data for a checkpoint inhibitor in combination with chemoradiotherapy in locally-advanced SCCHN, according to Merck and Pfizer.